Why Farbe Firma is the Top Manufacturer of Teicoplanin for Injection
- Maulik Sudani
- 12 hours ago
- 7 min read
Last Updated: May 31, 2026
TL;DR: Teicoplanin for Injection — a sterile lyophilised powder of the glycopeptide antibiotic teicoplanin, supplied most commonly as 200 mg and 400 mg vials for reconstitution with water for injection — is a front-line agent against serious Gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA) and other resistant staphylococci and streptococci: infective endocarditis, bone and joint infection, complicated skin and soft-tissue infection, and Gram-positive infection in febrile neutropenia. Its long elimination half-life supports once-daily dosing and outpatient parenteral antibiotic therapy (OPAT), and intramuscular as well as intravenous administration. Because teicoplanin is a complex of several closely related components whose ratio must be controlled, its efficacy and safety depend on a tightly defined component profile and a clean, fast-reconstituting lyophilised cake. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Teicoplanin for Injection at our Gujarat, India facility and supplies it to hospital pharmacy, infectious-disease services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Glycopeptide antibiotic — Teicoplanin for Injection is a front-line agent for serious Gram-positive infections including MRSA, infective endocarditis, bone and joint infection, complicated skin and soft-tissue infection and Gram-positive infection in febrile neutropenia. Its long half-life supports once-daily IV or IM dosing and OPAT.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, qualified lyophilisation (freeze-drying) lines for vials, dedicated control of a multi-component glycopeptide whose component ratio and reconstitution behaviour must be held batch to batch, with validated lyophilisation cycles, shelf mapping and container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, drug master files and CEP-style documentation for registrations including ministry-of-health, antimicrobial-programme and hospital tenders.
End-to-end CDMO services: Contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tender-ready vial-and-diluent packaging and logistics coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Teicoplanin for Injection Demands a Premium Manufacturer
Teicoplanin for Injection occupies a high-stakes place on the antimicrobial shelf. It is one of the glycopeptide antibiotics that infectious-disease physicians depend on when an infection is caused by a resistant Gram-positive organism — methicillin-resistant Staphylococcus aureus, coagulase-negative staphylococci, enterococci or resistant streptococci — and a beta-lactam will not work. It is used to treat infective endocarditis, bone and joint infection such as osteomyelitis and prosthetic-joint infection, complicated skin and soft-tissue infection, and Gram-positive sepsis in febrile neutropenic patients. Its long elimination half-life allows once-daily dosing after a loading regimen, and it can be given by intramuscular as well as intravenous routes, which together make it a mainstay of outpatient parenteral antibiotic therapy (OPAT). In every one of these settings the patient is seriously ill, and the dose must be both potent and reliably reconstituted.
That clinical reality places real demands on the manufacturer. Teicoplanin is not a single molecule but a complex of several closely related components (the major A2 components together with A3-1), produced by fermentation, and its antibacterial activity and tolerability depend on that component ratio being controlled within defined limits. It is supplied as a lyophilised (freeze-dried) powder because the reconstituted solution is not stable enough for long-term storage, and the freeze-dried cake must dissolve quickly and completely, without the persistent foaming that teicoplanin is prone to, so that ward staff can prepare an accurate dose at the bedside. The lyophilisation cycle — freezing, primary vacuum drying and secondary drying to a tightly controlled residual-moisture level — is a process discipline in its own right. Choosing a Teicoplanin for Injection manufacturer that treats component-profile control, lyophilisation, reconstitution behaviour and container-closure integrity as core engineering disciplines is what protects the patient with a serious Gram-positive infection at the bedside.
What Sets a World-Class Teicoplanin for Injection Manufacturer Apart
A world-class manufacturer of Teicoplanin for Injection invests in three areas that weaker suppliers underfund: control of the multi-component glycopeptide profile by HPLC so that every batch matches the reference composition and potency, a validated lyophilisation cycle that yields an elegant, fast-reconstituting cake with low residual moisture and minimal foaming, and tender-ready dossier support for a product procured almost entirely through hospital, antimicrobial-programme and ministry-of-health channels. It starts with the active — pharmacopoeial-grade teicoplanin sourced from qualified, audited fermentation-API makers, with full component-ratio and impurity profiling, microbiological potency assay and certificates of analysis verified by the receiving laboratory before the material enters production.
Formulation, filling and lyophilisation then have to preserve both the component profile and the dose. The bulk solution is compounded at controlled pH with appropriate buffering and bulking, sterile-filtered through 0.22 µm membrane, filled aseptically into clear-glass vials under ISO Class 5 air and then freeze-dried on validated shelves. The cycle parameters — freezing rate, sublimation pressure, secondary-drying time and final residual moisture — are locked in the master batch record, because residual moisture governs both the long shelf life and the speed of reconstitution. The vial is stoppered under partial vacuum or inert gas with a lyophilisation stopper; in-process and release testing confirm potency, the component ratio, reconstitution time and the clarity of the reconstituted solution.
Quality Systems Behind Every Teicoplanin for Injection
Every Farbe Firma Teicoplanin for Injection batch is released only after a full stack of quality checks: microbiological and HPLC potency assay against USP, BP, IP or EP reference standards, control of the teicoplanin component ratio (A2 components and A3-1) and related substances by HPLC, residual moisture by Karl Fischer titration, reconstitution time and appearance of the reconstituted solution, pH and osmolarity, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, container-closure integrity and fill-weight verification for the 200 mg and 400 mg vial formats. Certificates of analysis are issued with full traceability back to the API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, calibrated sterilisation and depyrogenation equipment, validated lyophilisation cycles with shelf and load mapping, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because teicoplanin is a multi-component glycopeptide whose ratio and residual moisture drive both efficacy and shelf life, we treat the component profile and Karl Fischer moisture result as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (30 °C / 65 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Teicoplanin for Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across anti-infective, critical-care, anaesthesia, oncology-supportive and supportive-care categories. For Teicoplanin for Injection specifically, we supply 200 mg and 400 mg lyophilised vials, with water-for-injection diluent ampoules, under WHO-GMP conditions, with country-specific formats and combined vial-and-diluent packs available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the lyophilisation-cycle validation and component-profile data package — ready to hand for registration.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, component-ratio and potency-method validation data, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics. When a buyer needs Teicoplanin for Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, lyophilisation-validation report, artwork, freeze-dryer slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the lyophilisation suite; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API component sourcing, lyophilisation-cycle development, residual-moisture control, reconstitution behaviour, potency assay, container-closure and stability choices in real detail. For a glycopeptide given to seriously ill patients with resistant Gram-positive infection, where potency and reliable reconstitution directly govern outcomes, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Teicoplanin for Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Teicoplanin for Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, qualified lyophilisation suites, qualified vial filling lines, qualified water-for-injection systems, validated freeze-drying cycles and continuous environmental monitoring.
Which strengths and pack sizes of Teicoplanin for Injection do you supply?
Our standard presentations are 200 mg and 400 mg teicoplanin as a lyophilised powder in clear-glass vials, supplied with a water-for-injection diluent ampoule in a combined carton. Custom pack configurations, multi-vial trays and country-specific artwork are available under contract manufacturing agreements.
Can Farbe Firma support country-specific registrations and component-profile data for Teicoplanin for Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, teicoplanin component-ratio and potency-method validation data, lyophilisation-cycle validation reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets.
How does Farbe Firma assure the quality and safety of Teicoplanin for Injection?
We control the teicoplanin component ratio and related substances by HPLC, run microbiological and HPLC potency assay against pharmacopoeial standards, verify residual moisture by Karl Fischer titration, qualify reconstitution time and solution clarity, lock the lyophilisation cycle to a validated profile, run particulate, endotoxin and sterility testing, and qualify each batch against ICH Q1A and ICH Q1B protocols.
What is the minimum order quantity for Teicoplanin for Injection contract manufacturing?
MOQs vary by vial strength, freeze-dryer load size, label complexity and dossier requirements. For the 200 mg and 400 mg presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments